Author Topic: (Abst.) MS patient cohorts and registries: how to maximize impact  (Read 98 times)

0 Members and 0 Guests are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 9480
  • MS diagnosed 1980
  • Location: Pacific Northwest
Some of the bigger names in the MS world are calling for better coordination of the efforts at collecting data on people MS in order to gain a better understanding of progressive MS.

From PubMed, March 11, 2017:

Mult Scler. 2017 Mar 1:1352458517698250.

Landscape of MS patient cohorts and registries: Recommendations for maximizing impact

Bebo BF Jr1, Fox RJ2, Lee K3, Utz U4, Thompson AJ5.

Author information

National Multiple Sclerosis Society, New York, NY, USA.
Mellen Center for Multiple Sclerosis, Cleveland Clinic, Cleveland, OH, USA.
Multiple Sclerosis Society of Canada, Toronto, ON, Canada.
Division of Extramural Research, National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health, Bethesda, MD, USA.
Institute of Neurology, Faculty of Brain Sciences, University College London, London, UK.


There is a growing number of cohorts and registries collecting phenotypic and genotypic data from groups of multiple sclerosis patients. Improved awareness and better coordination of these efforts is needed.


The purpose of this report is to provide a global landscape of the major longitudinal MS patient data collection efforts and share recommendations for increasing their impact.


A workshop that included over 50 MS research and clinical experts from both academia and industry was convened to evaluate how current and future MS cohorts could be better used to provide answers to urgent questions about progressive MS.


The landscape analysis revealed a significant number of largely uncoordinated parallel studies. Strategic oversight and direction is needed to streamline and leverage existing and future efforts. A number of recommendations for enhancing these efforts were developed.


Better coordination, increased leverage of evolving technology, cohort designs that focus on the most important unanswered questions, improved access, and more sustained funding will be needed to close the gaps in our understanding of progressive MS and accelerate the development of effective therapies.
MS Speaks--online for 16 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) since 12/16/20.


Related Topics

  Subject / Started by Replies Last post
0 Replies
Last post April 28, 2017, 02:53:29 pm
by agate
0 Replies
Last post October 16, 2018, 02:57:48 pm
by agate
0 Replies
Last post November 02, 2018, 07:30:04 am
by agate
0 Replies
Last post December 18, 2021, 08:51:29 pm
by agate
0 Replies
Last post November 12, 2022, 09:33:17 pm
by agate